Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study

Tislelizumab plus induction chemotherapy followed by nimotuzumab with chemoradiotherapy significantly improved tumor response, superior progression-free survival, and manageable safety for high-risk LANPC. However, our study demonstrates the potential benefits of combining nimotuzumab with chemoradiotherapy after neoadjuvant chemotherapy in high-risk LANPC patients; the findings are preliminary and must be validated by larger, more rigorously designed trials.